Guo et al. reported that emodin can enhance the antitumor effect of gemcitabine (the gold standard chemotherapy drug for PC) by inhibiting MDR1/P glycoprotein, MRP expression, and the IKKβ/NF-κB signaling pathway 162. Here, IKBKB is linked to pachyonychia congenita.